NCT03357224 2024-02-22PARCTEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2 Terminated26 enrolled
NCT02659384 2023-03-14Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian CancerEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2 Completed122 enrolled